Paper21828126
A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia.
Lee JH and 18 others. Blood, 2011. Cited by 117 papers, by iCite.
Cite this record
ConductScience Library. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Papers, record 21828126. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21828126
- Disease
- acute myeloid leukemia587 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibiotics, Antineoplastic | Major topic |
| Daunorubicin | Major topic |
| Leukemia, Myeloid, Acute | Major topic |
| Adolescent | |
| Adult | |
| Disease-Free Survival | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Male | |
| Middle Aged | |
| Prognosis | |
| Remission Induction | |
| Treatment Outcome | |
| Young Adult |
Source PubMed
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT00474006 | High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT06483906 | Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML. | Background | ClinicalTrials.gov |
Cited by61
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 117 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41986965 | Daunorubicin-45 Vs. Daunorubicin-60 for Induction in Intermediate-Age Patients of AML: Results From a Randomized Trial. | Cancer Sci | 2026 | https://conductscience.org/library/papers/41986965 | PubMed |
| 41073560 | Heart failure in patients with acute myeloid leukemia (AML) treated with anthracycline agents during remission induction therapy: a systematic review and meta-analysis. | Leukemia | 2026 | https://conductscience.org/library/papers/41073560 | PubMed |
| 40481098 | Early replacement of re-induction therapy following failed intensive induction treatment enhances the therapeutic efficacy of newly diagnosed AML. | Sci Rep | 2025 | https://conductscience.org/library/papers/40481098 | PubMed |
| 40147876 | Pegylated Liposomal Doxorubicin Combined with Cytarabine and Granulocyte Colony-Stimulating Factor for Treating Newly Diagnosed Older and Unfit Acute Myeloid Leukemia Patients: A Prospective, Single-Center, Single-arm, Phase II Study. | Technol Cancer Res Treat | 2025 | https://conductscience.org/library/papers/40147876 | PubMed |
| 39415901 | Acute myeloid leukemia presenting with hepatic dysfunction: Should induction be dose reduced? | EJHaem | 2024 | https://conductscience.org/library/papers/39415901 | PubMed |
| 38317981 | Spectrum of infections in different regimens of post-induction chemotherapy in acute myeloid leukemia (de-novo): A comparative retrospective study. | Heliyon | 2024 | https://conductscience.org/library/papers/38317981 | PubMed |
| 38066853 | Improving long-term outcomes with intensive induction chemotherapy for patients with AML. | Hematology Am Soc Hematol Educ Program | 2023 | https://conductscience.org/library/papers/38066853 | PubMed |
| 37274294 | Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia. | Front Oncol | 2023 | https://conductscience.org/library/papers/37274294 | PubMed |
| 36276074 | Treatment options for acute myeloid leukemia patients aged <60 years. | Front Oncol | 2022 | https://conductscience.org/library/papers/36276074 | PubMed |
| 36077703 | A Focus on Intermediate-Risk Acute Myeloid Leukemia: Sub-Classification Updates and Therapeutic Challenges. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36077703 | PubMed |
| 35937938 | Profile of Glasdegib for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML): Evidence to Date. | Cancer Manag Res | 2022 | https://conductscience.org/library/papers/35937938 | PubMed |
| 35898381 | Intensified-Dose Chemotherapy in Combination With Gemtuzumab-Ozogamicin for the Treatment of Favorable-Risk Acute Myeloid Leukemia (AML). | Cureus | 2022 | https://conductscience.org/library/papers/35898381 | PubMed |
| 35847688 | Combination of cyclophosphamide and cytarabine as induction regimen for newly diagnosed adult acute myeloid leukemia. | EJHaem | 2020 | https://conductscience.org/library/papers/35847688 | PubMed |
| 35734931 | Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience. | Haematologica | 2022 | https://conductscience.org/library/papers/35734931 | PubMed |
| 35231903 | Chemotherapy or Allogeneic Stem Cell Transplantation as Salvage Therapy for Patients with Refractory Acute Myeloid Leukemia: A Multicenter Analysis. | Acta Haematol | 2022 | https://conductscience.org/library/papers/35231903 | PubMed |
| 34596937 | Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group. | Pediatr Blood Cancer | 2021 | https://conductscience.org/library/papers/34596937 | PubMed |
| 34350512 | 3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye? | Curr Oncol Rep | 2021 | https://conductscience.org/library/papers/34350512 | PubMed |
| 34320781 | Dose intensity for induction in acute myeloid leukemia: what, when, and for whom? | Haematologica | 2021 | https://conductscience.org/library/papers/34320781 | PubMed |
| 34031004 | Outcomes of Adult Acute Myeloid Leukemia Treated With Gemtuzumab-Ozogamicin: Cue To Optimized Chemotherapy Backbone. | Clin Lymphoma Myeloma Leuk | 2021 | https://conductscience.org/library/papers/34031004 | PubMed |
| 33666716 | Protective effects of curcumin on chemical and drug-induced cardiotoxicity: a review. | Naunyn Schmiedebergs Arch Pharmacol | 2021 | https://conductscience.org/library/papers/33666716 | PubMed |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| DAUNORUBICIN | CHEMBL178 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL178 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/21828126
GET https://conductscience.org/api/papers/v1/21828126/cited_by?page=2